{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-062058","form_type":"8-K","ticker":"LIMN","cik":"0001971387","company_name":"Liminatus Pharma, Inc.","filed_at":"2025-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.598729+00:00","generated_at":"2026-05-18T23:00:44.650289+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Liminatus Pharma advances IBA101 CD47 inhibitor toward IND submissions in H2 2026","bullets":["Completed GLP toxicology studies at Charles River; no clinically meaningful hemoglobin or platelet reductions in primates.","Plans simultaneous IND submissions to FDA and Korea's MFDS in H2 2026; site activations and patient screening start early 2027.","Partnered with Dr. Se-Hoon Lee at Samsung Medical Center for Phase 1 trial in NSCLC, including 3+3 dose-escalation and PD-1/PD-L1 combination arms.","Preclinical combination data with PD-1/PD-L1 inhibitors showed increased complete response rates versus monotherapy.","Engineered epitope selectivity and Fc modifications designed to avoid anemia/thrombocytopenia that halted earlier CD47 programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-062058","json":"https://secwatch.observer/filing/0001104659-25-062058.json","markdown":"https://secwatch.observer/filing/0001104659-25-062058.md","text":"https://secwatch.observer/filing/0001104659-25-062058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971387/000110465925062058/0001104659-25-062058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971387/000110465925062058/tm2518817d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T23:00:44.650289+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}